Regional Cardiac Denervation Predicts Sustained Ventricular Arrhythmias in Nonischemic Cardiomyopathy Patients Without LGE on CMR Imaging.

Background: In patients with nonischemic cardiomyopathy and no late gadolinium enhancement (LGE) on cardiac magnetic resonance, risk prediction for the occurrence of sustained ventricular arrhythmias (VA) is challenging. Global and regional sympathetic denervation has been associated with VA in patients with ischemic cardiomyopathy. Its prognostic relevance in nonischemic cardiomyopathy is unknown.

Fibroblast activation protein-expression in colorectal carcinomas and implications for clinical application.

Background: Colorectal cancer is highly prevalent. The stromal tumour microenvironment significantly influences tumour behaviour, and cancer-associated fibroblasts (CAFs), as major component of tumour stroma, are increasingly studied. Specifically, CAF-marker fibroblast activation protein (FAP) is gaining interest as tracer for imaging using radiolabelled FAP-inhibitor (FAPI).

An exploratory assessment of early and delta PET radiomic features for outcome prediction in locally advanced cervical cancer.

Purpose: This study investigated whether radiomic features extracted from [F]FDG-PET scans acquired before and two weeks after neoadjuvant treatment, and their variation, provided prognostic parameters in locally advanced cervical cancer (LACC) patients treated with neoadjuvant chemo-radiotherapy (CRT) followed by radical surgery.

Methods: We retrospectively included LACC patients referred to our Institution from 2010 to 2016. [F]FDG-PET/CT was performed before neoadjuvant CRT (baseline) and two weeks after the start of treatment (early).

Multicollinearity and redundancy of the PET radiomic feature set.

Introduction: The aim of this study was to map multicollinearity of the radiomic feature set in five independent [F]FDG-PET cohorts with different tumour types and identify generalizable non-redundant features.

Methods: Five [F]FDG-PET radiomic cohorts were analysed: non-small cell lung carcinomas (N = 35), pheochromocytomas and paragangliomas (N = 40), head and neck squamous cell carcinomas (N = 54), [F]FDG-positive thyroid nodules with indeterminate cytology (N = 84), and gastric carcinomas (N = 206). Lesions were delineated, and 105 radiomic features were extracted using PyRradiomics.

Can Molecular Breast Imaging With Tc-99m Sestamibi Safely Rule Out Malignancy in Pathologic Nipple Discharge?

Purpose: Nipple discharge is the third most common breast-related complaint. It is recommended to exclude malignancy in pathologic nipple discharge (PND). Mammography and ultrasound are the first-line conventional diagnostic (CD) imaging.

Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [F]FDG in gynaecological malignancies: systematic literature review and meta-analysis.

Purpose: This study aims to systematically review and perform a meta-analysis to compare the diagnostic performance of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and 2-deoxy-2-[F]fluoro-D-glucose ([F]FDG) in gynaecological cancers.

Methods: A comprehensive search of PubMed/MEDLINE and EMBASE was conducted and updated to October 25, 2024, to identify clinical studies evaluating FAPI and [F]FDG PET/CT or PET/MR in patients with gynaecological cancer. Quality was assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies).

Neovascular prostate specific membrane antigen (PSMA) expression in bone and soft tissue sarcoma: a systematic analysis.

Bone and soft tissue sarcomas are a highly heterogeneous group of rare cancers of mesenchymal origin. Treatment options other than surgery have limited efficacy due to low response rates with some exceptions. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may provide a novel treatment option, as it was recently suggested that soft tissue sarcomas express PSMA in the neovasculature, and on PET/CT imaging, multiple sarcomas have shown intense PSMA-tracer accumulation.

Diagnostic Performance of Radiolabelled FAPI Versus [F]FDG PET Imaging in Hepato-Pancreato-Biliary Oncology: A Systematic Review and Meta-Analysis.

Radiolabelled fibroblast activation protein inhibitor (FAPI) tracers have the potential to overcome the limitations of 2-deoxy-2-[F]fluoro-D-glucose ([F]FDG) and improve the diagnosis and staging of hepato-pancreato-biliary (HPB) cancers. This study aims to compare the diagnostic performance of radiolabelled FAPI versus [F]FDG PET imaging in HPB cancers. A systematic search of PubMed, Embase, Web of Science and Cochrane Library was performed to identify eligible studies on the diagnostic performance of FAPI PET for primary HPB tumours (hepatocellular carcinoma (HCC), pancreatic cancer (PC) and biliary tract cancer (BTC)) and for liver metastases of gastrointestinal origin.

[F]FDG administered activity reduction capabilities of a 32-cm axial field-of-view solid-state digital bismuth germanium oxide PET/CT system while maintaining EARL compliance.

Purpose: To assess the lower [F]FDG limit in administered activity and/or scan time reduction capabilities of a digital-BGO 32-cm axial field-of-view PET system while being compliant with current and updated EANM Research Ltd Fluorine-18 accreditation specifications (EARL and EARL).

Methods: EARL and EARL compliance of the digital-BGO system (Omni Legend 32 cm) was tested for several reconstructions, including those that apply precision deep learning-based image enhancement (PDL) as postprocessing, using the calibration QC and NEMA IEC phantom measurements. The image quality QC scan was repeated every hour for 7 h, with each subsequent hour representing a lower administered activity, and reconstructed for various times per bed position, i.

Monitoring neoadjuvant treatment-induced surgical benefit in GIST patients using CT-based radiological criteria.

Objective: This single-centre retrospective study aims to determine the incidence of therapy-induced surgical benefit in patients with non-metastatic gastrointestinal stromal tumour (GIST) treated with neoadjuvant tyrosine kinase inhibitors (TKI) and evaluate whether this can be predicted by radiological response criteria.

Methods: Thirty-nine non-metastatic GIST patients were treated with neoadjuvant TKI treatment, followed by curative-intended surgery, and monitored using contrast-enhanced computed tomography (CE-CT). Surgical benefit was independently assessed by two surgical oncologists and was defined by de-escalation of surgical strategy or reduced surgical complexity.

Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients.

Objective: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with varying survival outcomes. This study investigated whether baseline PSMA PET/CT parameters are associated with survival and treatment response.

Methods: Sixty mCRPC patients underwent [F]PSMA-1007 PET/CT before treatment with androgen receptor-targeted agents (ARTAs) or chemotherapy.

Selecting Targets for Molecular Imaging of Gastric Cancer: An Immunohistochemical Evaluation.

Purpose: Tumor-targeted positron emission tomography (PET) and fluorescence-guided surgery (FGS) could address current challenges in pre- and intraoperative imaging of gastric cancer. Adequate selection of molecular imaging targets remains crucial for successful tumor visualization. This study evaluated the potential of integrin αβ, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM) and human epidermal growth factor receptor-2 (HER2) for molecular imaging of primary gastric cancer, as well as lymph node and distant metastases.

A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET/CT for Therapy Response Monitoring in Oncology.

Background And Objective: This systematic literature review addresses model-based cost-effectiveness studies for therapy response monitoring with positron emission tomography (PET) generally combined with low-dose computed tomography (CT) for various cancer types. Given the known heterogeneity in therapy response events, studies should consider patient-level modelling rather than cohort-based modelling because of its flexibility in handling these events and the time to events. This review aims to identify the modelling methods used and includes a systematic assessment of the assumptions made in the current literature.

Integrating Clinical Variables, Radiomics, and Tumor-derived Cell-Free DNA for Enhanced Prediction of Resectable Esophageal Adenocarcinoma Outcomes.

Purpose: The value of integrating clinical variables, radiomics, and tumor-derived cell-free DNA (cfDNA) for the prediction of survival and response to chemoradiation of patients with resectable esophageal adenocarcinoma is not yet known. Our aim was to investigate if radiomics and cfDNA metrics combined with clinical variables can improve personalized predictions.

Methods And Materials: A cohort of 111 patients with resectable esophageal adenocarcinoma from 2 centers treated with neoadjuvant chemoradiation therapy was used for exploratory retrospective analyses.

Arterial inflammation on [F]FDG PET/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I.

Background And Aims: Immune checkpoint inhibitors (ICIs) revolutionized cancer treatment. However, ICIs may increase the immune response to non-tumor cells, possibly resulting in increased arterial inflammation, raising the risk of atherosclerotic events. Nevertheless, malignancies may induce a pro-inflammatory state and the association between ICIs and arterial inflammation remains to be clarified.

Role of [F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines.

Purpose: The recently released EANM/SNMMI guideline, endorsed by several important clinical and imaging societies in the field of breast cancer (BC) care (ACR, ESSO, ESTRO, EUSOBI/ESR, EUSOMA), emphasized the role of [F]FDG PET/CT in management of patients with no special type (NST) BC. This review identifies and summarizes similarities, discrepancies and novelties of the EANM/SNMMI guideline compared to NCCN, ESMO and ABC recommendations.

Methods: The EANM/SNMMI guideline was based on a systematic literature search and the AGREE tool.